New pill for type 2 diabetes
There have been several new pills approved for type 2 diabetes in recent years. Here are a few examples:
- Ozempic (semaglutide): Approved in 2017, Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps the body produce insulin and reduce blood sugar levels. It is taken once a week by injection.
- Farxiga (dapagliflozin): Approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that helps the body remove excess glucose from the urine. It is taken once a day by mouth.
- Invokana (canagliflozin): Approved in 2013, Invokana is also an SGLT2 inhibitor that helps the body remove excess glucose from the urine. It is taken once a day by mouth.
- Jardiance (empagliflozin): Approved in 2014, Jardiance is another SGLT2 inhibitor that helps the body remove excess glucose from the urine. It is taken once a day by mouth.
- Trulicity (dulaglutide): Approved in 2014, Trulicity is a GLP-1 receptor agonist that helps the body produce insulin and reduce blood sugar levels. It is taken once a week by injection.
- Glyxambi (empagliflozin and linagliptin): Approved in 2014, Glyxambi is a combination pill that contains an SGLT2 inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is taken once a day by mouth.
- Xultophy (insulin degludec and liraglutide): Approved in 2016, Xultophy is a combination pill that contains a long-acting insulin and a GLP-1 receptor agonist. It is taken once a day by injection.
- Rybelsus (semaglutide): Approved in 2019, Rybelsus is an oral version of Ozempic, a GLP-1 receptor agonist. It is taken once a day by mouth.
- Zynquista (sotagliflozin): Approved in 2019, Zynquista is an SGLT1 and SGLT2 inhibitor that helps the body remove excess glucose from the urine. It is taken once a day by mouth.
It's important to note that each of these medications has its own unique benefits and risks, and they may not be suitable for everyone. It's important to talk to your doctor or healthcare provider to determine the best treatment plan for your type 2 diabetes.